Latest Posts

Are gene-editing therapies patentable? A WIPO side event investigates.

On 6 December, Knowledge Ecology International (KEI) organised an interesting panel on the patentability of new gene- and cell-based medical therapies, as a side...

New Database Documents the Power of TRIPS Flexibilities

Medicines Law & Policy has published an on-line database of instances of the use of TRIPS flexibilities in public health contexts, titled the TRIPS...

New Tool Maps Use of TRIPS Flexibilities for Public Health

Flexibilities were essential in providing access to HIV medicines; today, the need for access to other essential treatments is driving their uptake 27 NOVEMBER 2018: Medicines Law & Policy today launches a new tool demonstrating how key...

WIPO and pharma industry launch global medicines patent database

On 25 September, the World Intellectual Property Organisation (WIPO) in collaboration with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) launched the Patent...

Dutch health insurance company Menzis takes AstraZeneca to court over patent evergreening

Today health insurance company Menzis announced  that it is taking the pharmaceutical company AstraZeneca to court over the pricing of Seroquel, a medicine...

CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests

On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation...

Subscribe to Our Newsletter

Never miss a post! Sign up for ML&P's mailing list by entering your information below. The list will only be used to inform you of new content (messages are sent approximately once a month).